REDUCE Bajaj Auto

Strong performance; rich valuations limit upside

Auto & Auto Ancillaries > Result Update > April 19, 2024

BJAUT reported strong performance that was in-line, with margins sustaining QoQ at 20.1% (Emkay est.: 20.4%). Domestic 2W recovery continues apace, even as revival in exports is expected to be slightly gradual. BJAUT is improving its positioning in the growing 125cc category, while also ramping-up well in E-3Ws (already has 60% share in some markets). However, amid the sharp runup in the stock price (valuations well above 1SD from LTA), we retain REDUCE, with revised TP of Rs7,900/share (23x core FY26E multiple + Rs800 cash/investment per share; upward revision on healthy positioning in E-3Ws, thereby restricting disruption threat to the high-margin 3W franchise. We buildin 12%/8% volume/EPS CAGR over FY24-26E. We still prefer TVSL in 2Ws (similar business model with bottom-up share gains, margin triggers).

Bajaj Auto: Financial Snapshot (Standalone)												
Y/E Mar (Rs mn)	FY22	FY23	FY24	FY25E	FY26E							
Revenue	3,31,447	3,64,276	4,46,852	5,38,284	5,87,026							
EBITDA	52,586	65,491	88,229	1,06,430	1,16,024							
Adj. PAT	47,761	56,276	74,788	87,488	94,359							
Adj. EPS (Rs)	165.1	198.9	271.8	317.9	342.9							
EBITDA margin (%)	15.9	18.0	19.7	19.8	19.8							
EBITDA growth (%)	6.7	24.5	34.7	20.6	9.0							
Adj. EPS growth (%)	10.2	14.7	36.7	17.0	7.9							
RoE (%)	18.4	21.6	29.7	35.0	37.6							
RoIC (%)	145.8	182.6	341.7	458.5	371.1							
P/E (x)	54.7	45.4	33.2	28.4	26.3							
EV/EBITDA (x)	45.6	36.0	25.8	21.5	19.7							
P/B (x)	9.8	10.0	10.0	9.9	9.9							
FCFF yield (%)	1.0	1.5	2.3	0.7	3.1							

Source: Company, Emkay Research

Strong performance; in-line results

Revenue rose 29% YoY to ~Rs114.8bn, amid 25% YoY higher volumes, with realization lower 6% QoQ. EBITDA margin was stable QoQ at 20.1%; lower RM sequentially was offset by higher other expenses on operating de-leverage. Consequently, adjusted PAT rose ~35% YoY to ~Rs19.3bn. BJAUT declared final dividend of Rs80/share for FY24.

Earnings call KTAs


1) Domestic 2W industry is expected to grow at 7-8% p.a. amid improving consumer sentiment; here, BJAUT aims to continue outperforming via new product introduction (e.g. upcoming big bike Pulsar; impending CNG motorcycle launch, which stretches the addressable market to mileage-conscious consumers; currently, the segment size is ~600K units/mth). 2) In export markets, macro challenges persist in most geographies, albeit at a lower level now; BJAUT remains cautious about prospects in certain markets like Nigeria and Bangladesh; other ASEAN and Latin American markets are recovering; BJAUT's overall expectations include exports growing YoY in FY25, with revenue clocking much better growth. 3) In domestic 3Ws, recovery from a low base is now complete, with growth seen moderating to a single-digit on organic basis; E-autos are seen driving growth in permit-restricted markets (45% of industry); BJAUT has 30% mkt share in addressed markets (60% in markets where it has had presence for 6 months). 4) Commencement of Qute sales to Egypt, to help partially mitigate the lower 3W sales. 5) Triumph footprint to expand to 150 stores in H1; portfolio to expand thereafter; Company has 20% mkt share in some southern markets. 6) Growth in E-2Ws is seen continuing, perhaps at a slower rate now; footprint to expand to 600 stores by H1 vs. 200 now; Company has planned 2 new products under the Chetak brand in coming months. 7) BJAUT has received PLI certificate for E-3Ws and Chetak; expects similar profitability in E-3Ws as that in ICE, after the PLI benefit, though E-2W profitability is some time away as cost actions are being outpaced by decline in price points. 8) Price of some metals like aluminium and copper have moved up; Company has taken a marginal price increase in Q1. 9) Financing share in 2Ws/3Ws is 75%/90%; 10) Spares revenue in Q4 is Rs13bn.



TARGET PRICE (Rs): 7,900

Target Price – 12M	Mar-25
Change in TP (%)	16.2
Current Reco.	REDUCE
Previous Reco.	REDUCE
Upside/(Downside) (%)	(12.4)
CMP (18-Apr-24) (Rs)	9,021.3
Stock Data	Ticker
52-week High (Rs)	9,358
52-week Low (Rs)	4,175
Shares outstanding (mn)	279.2
Market-cap (Rs bn)	2,519
Market-cap (USD mn)	30,147
Net-debt, FY25E (Rs mn)	-1,97,271
ADTV-3M (mn shares)	1
ADTV-3M (Rs mn)	4,484.9
ADTV-3M (USD mn)	53.7
Free float (%)	45.0
Nifty-50	21,996
INR/USD	83.5
Shareholding, Dec-23	
Promoters (%)	54.9
FPIs/MFs (%)	14.7/8.7

Price Performance									
(%)	1M	3M	12M						
Absolute	5.9	27.4	114.3						
Rel. to Nifty 6.0 24.9 72									



Chirag Jain

chirag.jain@emkayglobal.com +91 22 6624 2428

Jaimin Desai

jaimin.desai@emkayglobal.com +91 22 6612 1334

Nandan Pradhan

nandan.pradhan@emkayglobal.com +91 22 6612 1238

This report is intended for team.emkay @ whitemarquesolutions.com use and downloaded at 05/15/2024 10:24 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

(Rs mn)	Q1FY23	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	YoY (%)	QoQ (%)
Revenue	80,050	1,02,028	93,151	89,047	1,03,098	1,07,773	1,21,135	1,14,847	29.0	(5.2)
Expenditure	67,080	84,440	75,383	71,882	83,558	86,444	96,836	91,784	27.7	(5.2)
as % of sales	83.8	82.8	80.9	80.7	81.0	80.2	79.9	79.9		
Consumption of RM	57,776	74,861	65,775	62,135	74,127	76,511	86,096	80,702	29.9	(6.3)
as % of sales	72.2	73.4	70.6	69.8	71.9	71.0	71.1	70.3		
Employee Cost	3,796	3,522	3,511	3,620	3,842	3,816	3,846	3,872	7.0	0.7
as % of sales	4.7	3.5	3.8	4.1	3.7	3.5	3.2	3.4		
Other expenditure	5,507	6,058	6,097	6,126	5,590	6,118	6,895	7,210	17.7	4.6
as % of sales	6.9	5.9	6.5	6.9	5.4	5.7	5.7	6.3		
EBITDA	12,970	17,587	17,768	17,166	19,539	21,329	24,299	23,063	34.4	(5.1)
EBITDA margin (%)	16.2	17.2	19.1	19.3	19.0	19.8	20.1	20.1		
Depreciation	673	670	740	742	835	876	881	906	22.1	2.8
EBIT	12,297	16,917	17,029	16,424	18,704	20,452	23,418	22,157	34.9	(5.4)
Other Income	3,193	3,332	2,691	2,598	3,463	3,614	3,461	3,487	34.2	0.7
Interest	43	109	85	157	121	65	121	228	44.7	88.3
РВТ	15,447	20,140	19,635	18,865	22,046	24,000	26,758	25,416	34.7	(5.0)
Total Tax	3,714	4,840	4,721	4,536	5,399	5,639	6,339	6,056	33.5	(4.5)
Adjusted PAT	11,733	15,300	14,914	14,329	16,648	18,361	20,419	19,360	35.1	(5.2)
Extra ordinary items Loss/(Gain)	0	0	0	0	0	0	0	0		
Reported PAT	11,733	15,300	14,914	14,329	16,648	18,361	20,419	19,360	35.1	(5.2)
Adjusted EPS (Rs)	40.5	53.9	52.7	50.6	58.8	64.9	72.2	68.4	35.1	(5.2)
(%)									(bps)	(bps)
EBITDAM	16.2	17.2	19.1	19.3	19.0	19.8	20.1	20.1	80	2
EBITM	15.4	16.6	18.3	18.4	18.1	19.0	19.3	19.3	85	(4)
EBTM	19.3	19.7	21.1	21.2	21.4	22.3	22.1	22.1	94	4
РАТМ	14.7	15.0	16.0	16.1	16.1	17.0	16.9	16.9	77	0
Effective Tax rate	24.0	24.0	24.0	24.0	24.5	23.5	23.7	23.8	(22)	14

Source: Company, Emkay Research

Exhibit 2: Q4FY24 – Actual vs estimates

(Rs mn)	Actual	Emkay Est	% variance	Consensus	% variance
Net sales	1,14,847	1,11,284	3.2	1,11,143	3.3
EBITDA	23,063	22,713	1.5	21,870	5.5
EBITDA margin (%)	20.1	20.4	-33 bps	19.7	40 bps
Adj net income	19,360	18,358	5.5	18,442	5.0
FDEPS (Rs)	68.4	64.9	5.5	65.2	5.0

Source: Company, Emkay Research

Exhibit 3: Margin analysis - EBITDA margin was stable QoQ at 20.1%; the sequentially lower RM was offset by higher other expenses on operating leverage.

Year to March (%)	Q4FY24	Q4FY23	Change (bps)	Q3FY24	Change (bps)
Raw material	70.3	69.8	49	71.1	(81)
Staff costs	3.4	4.1	(69)	3.2	20
Other expenses (incl expenses capitalized)	6.3	6.9	(60)	5.7	59
EBITDA	20.1	19.3	80	20.1	2
Adjusted net profit	16.9	16.1	77	15.4	148
Tax rate	23.8	24.0	(22)	23.7	14

Source: Company, Emkay Research

This report is intended for team emkay@whitemarguesolutions com use and downloaded at 05/15/2024 10:24 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO-.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

BJAUT mix (%)	Q1FY23	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24
Dom. Motorcycles	33.0	53.1	45.2	47.1	50.8	45.6	51.4	46.9
Upto 110cc	10.0	22.3	14.5	12.6	13.5	13.4	15.0	10.2
110-125cc	16.1	16.9	16.9	19.2	23.3	16.9	20.1	19.4
125-150cc	2.8	7.3	5.7	5.1	5.1	5.8	7.3	8.0
Over 150cc	4.1	6.6	8.2	10.2	8.9	9.6	9.0	9.3
Dom. Scooters	0.7	0.9	1.1	1.1	2.1	2.3	3.1	4.3
Dom. 2W	33.7	54.0	46.3	48.3	52.8	47.9	54.6	51.2
Export 2W	57.1	34.6	40.3	36.1	33.7	35.7	32.0	34.6
Total 2W	90.7	88.5	86.6	84.4	86.6	83.6	86.6	85.8
Dom. 3W	4.1	6.3	9.0	11.6	9.6	12.5	10.2	10.3
Export 3W	5.1	5.1	4.3	3.9	3.7	3.7	3.1	3.7
Total 3W	9.2	11.4	13.4	15.5	13.3	16.3	13.3	14.1
Total Quadricycles	0.1	0.0	0.1	0.2	0.1	0.1	0.1	0.1
Total domestic	37.8	60.3	55.4	59.9	62.4	60.5	64.8	61.5
Total exports	62.2	39.7	44.6	40.1	37.6	39.5	35.2	38.5
Grand total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Source: SIAM, Emkay Research

BJAUT market share (%)	Q1FY23	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24
Dom. Motorcycles	12.8	20.4	17.6	17.7	19.1	16.5	20.0	17.2
Upto 110cc	7.3	17.2	11.5	8.9	10.3	10.0	11.9	7.9
110-125cc	21.8	23.9	24.6	32.6	31.4	22.1	29.2	25.9
125-150cc	33.6	58.8	61.7	46.6	49.2	57.6	57.4	50.8
Over 150cc	10.6	13.9	15.3	18.7	17.4	17.1	18.3	17.4
Dom. Scooters	0.5	0.6	0.9	0.8	1.6	1.6	2.5	3.1
Dom. 2W	8.4	13.3	11.8	11.5	13.1	11.0	13.9	12.1
Export 2W	46.4	41.6	46.8	44.3	43.8	42.1	44.9	40.4
Total 2W	17.4	18.1	18.1	16.8	18.0	16.0	18.6	16.9
Dom. 3W	50.2	60.7	64.2	64.9	68.2	67.6	65.5	66.9
Export 3W	49.0	50.8	46.8	53.5	52.4	48.1	49.6	56.8
Total 3W	49.6	55.9	57.3	61.6	62.9	61.8	61.0	63.9

Source: SIAM, Emkay Research

This report is intended for team emkay@whitemarquesolutions.com use and downloaded at 05/15/2024 10:24 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Revenue Model	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E	FY26E
Domestic 2Ws (units)	2,541,320	2,078,348	1,809,375	1,641,084	1,803,748	2,250,585	2,554,147	2,781,170
Growth (%)	28.7	(18.2)	(12.9)	(9.3)	9.9	24.8	13.5	8.9
Domestic 3Ws (units)	398,826	364,817	109,304	160,599	300,009	464,138	487,345	501,965
Growth (%)	7.9	(8.5)	(70.0)	46.9	86.8	54.7	5.0	3.0
Domestic Total (units)	2,940,146	2,443,165	1,918,679	1,801,683	2,103,757	2,714,723	3,041,492	3,283,135
Growth (%)	25.4	(16.9)	(21.5)	(6.1)	16.8	29.0	12.0	7.9
Export 2Ws (units)	1,695,553	1,869,220	1,796,518	2,195,772	1,636,956	1,477,338	1,802,352	1,928,517
Growth (%)	21.6	10.2	(3.9)	22.2	(25.4)	(9.8)	22.0	7.0
Export 3Ws (units)	383,177	301,885	257,729	310,854	184,284	161,198	193,437	208,912
Growth (%)	43.1	(21.2)	(14.6)	20.6	(40.7)	(12.5)	20.0	8.0
Export Total (units)	2,078,730	2,171,105	2,054,247	2,506,626	1,821,240	1,638,536	1,995,789	2,137,429
Growth (%)	25.0	4.4	(5.4)	22.0	(27.3)	(10.0)	21.8	7.1
Total volumes (units)	5,018,876	4,614,270	3,972,926	4,308,309	3,924,997	4,353,259	5,037,282	5,420,564
Growth (%)	25.3	(8.1)	(13.9)	8.4	(8.9)	10.9	15.7	7.6
ASP (Rs/unit)	60,479	64,826	69,826	76,930	92,792	102,703	106,841	108,278
Growth (%)	(3.9)	7.2	7.7	10.2	20.6	10.7	4.0	1.3
Revenues (Rs mn)	303,576	299,187	277,411	331,447	364,276	446,852	538,284	587,026
Growth (%)	20.4	(1.4)	(7.3)	19.5	9.9	22.7	20.5	9.1
EBITDA (Rs mn)	51,925	50,962	49,285	52,586	65,491	88,229	106,430	116,024
EBITDA margin (%)	17.1	17.0	17.8	15.9	18.0	19.7	19.8	19.8
EBITDA growth (%)	7.3	(1.9)	(3.3)	6.7	24.5	34.7	20.6	9.0
EBIT (Rs mn)	63,656	65,834	59,457	61,987	74,481	98,755	115,709	124,810
EBIT margin (%)	21.0	22.0	21.4	18.7	20.4	22.1	21.5	21.3
EPS (Rs)	153	176	157	165	199	268	313	338

Source: Company, Emkay Research

Exhibit 7: Change in estimates

		FY	24			FY2	5E			FY2	6E	
(Rs mn)	Earlier	Revised	% Change	% YoY	Earlier	Revised	% Change	% YoY	Earlier	Revised	% Change	% YoY
Domestic 2W	2,291,702	2,250,585	(1.8)	24.8	2,554,147	2,554,147	-	13.5	2,781,170	2,781,170	-	8.9
Domestic 3W	471,920	465,044	(1.5)	54.6	471,920	488,251	3.5	5.0	471,920	502,871	6.6	3.0
Total Domestic	2,763,622	2,715,629	(1.7)	29.0	3,026,068	3,042,398	0.5	12.0	3,253,090	3,284,041	1.0	7.9
Export 2W	1,522,369	1,477,338	(3.0)	(9.8)	2,024,751	1,802,352	(11.0)	22.0	2,146,236	1,928,517	(10.1)	7.0
Export 3W	157,029	161,198	2.7	(12.5)	214,734	193,437	(9.9)	20.0	227,618	208,912	(8.2)	8.0
Total Export	1,679,398	1,638,536	(2.4)	(10.0)	2,239,485	1,995,789	(10.9)	21.8	2,373,854	2,137,429	(10.0)	7.1
Volumes (Units)	4,443,021	4,350,933	(2.1)	10.8	5,265,553	5,038,188	(4.3)	15.8	5,626,945	5,421,470	(3.7)	7.6
Revenues	448,582	446,852	(0.4)	22.7	533,363	538,284	0.9	20.5	580,938	587,026	1.0	9.1
EBITDA	87,939	88,229	0.3	34.7	104,429	106,430	1.9	20.6	113,819	116,024	1.9	9.0
Margin (%)	19.6	19.7	14 bps	177 bps	19.6	19.8	19 bps	3 bps	19.6	19.8	17 bps	-1 bps
Net Profit	73,831	74,788	1.3	32.9	86,046	87,488	1.7	17.0	92,769	94,359	1.7	7.9
EPS (Rs)	264.7	267.9	1.2	34.7	308.5	313.4	1.6	17.0	332.6	338.0	1.6	7.9

Source: Emkay Research


This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 05/15/2024 10:24 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 8: Emkay vs Consensus estimates

Bajaj Auto (Rs mn)	Emkay Estimates			Bloom	berg estima	tes	Difference (%)		
	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E
Net revenue	446,852	538,284	587,026	441,040	505,972	578,442	1.3%	6.4%	1.5%
EBITDA	88,229	106,430	116,024	87,174	100,061	115,105	1.2%	6.4%	0.8%
EBITDA margin (%)	19.7	19.8	19.8	19.8	19.8	19.9	-0.1%	0.0%	-0.7%
EPS (Rs)	268	313	338	261	300	343	2.5%	4.5%	-1.5%

Source: Bloomberg, Emkay Research





Source: Bloomberg, Emkay Research

Bajaj Auto: Standalone Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY22	FY23	FY24	FY25E	FY26E
Revenue	3,31,447	3,64,276	4,46,852	5,38,284	5,87,026
Revenue growth (%)	19.5	9.9	22.7	20.5	9.1
EBITDA	52,586	65,491	88,229	1,06,430	1,16,024
EBITDA growth (%)	6.7	24.5	34.7	20.6	9.0
Depreciation & Amortization	2,692	2,824	3,498	3,824	4,339
EBIT	49,895	62,667	84,731	1,02,606	1,11,685
EBIT growth (%)	6.9	25.6	35.2	21.1	8.8
Other operating income	0	0	0	0	0
Other income	12,092	11,814	14,025	13,104	13,124
Financial expense	87	395	535	594	653
РВТ	61,901	74,086	98,220	1,15,115	1,24,156
Extraordinary items	0	0	0	0	0
Taxes	14,139	17,810	23,432	27,628	29,798
Minority interest	0	0	0	0	0
Income from JV/Associates	0	0	0	0	0
Reported PAT	50,189	56,276	74,788	87,488	94,359
PAT growth (%)	10.2	12.1	32.9	17.0	7.9
Adjusted PAT	47,761	56,276	74,788	87,488	94,359
Diluted EPS (Rs)	165.1	198.9	271.8	317.9	342.9
Diluted EPS growth (%)	10.2	14.7	36.7	17.0	7.9
DPS (Rs)	140.0	140.0	140.0	310.0	340.0
Dividend payout (%)	80.7	70.4	51.5	97.5	99.2
EBITDA margin (%)	15.9	18.0	19.7	19.8	19.8
EBIT margin (%)	15.1	17.2	19.0	19.1	19.0
Effective tax rate (%)	22.8	24.0	23.9	24.0	24.0
NOPLAT (pre-IndAS)	38,498	47,602	64,517	77,980	84,881
Shares outstanding (mn)	289.4	283.0	275.2	275.2	275.2

Balance Sheet					
Y/E Mar (Rs mn)	FY22	FY23	FY24	FY25E	FY26E
Share capital	2,894	2,830	2,792	2,792	2,792
Reserves & Surplus	2,63,794			2,47,995	
Net worth	2,66,688			2,50,787	2,51,585
Minority interests	0	0	0	0	, , , , , , , , , , , , , , , , , , ,
Deferred tax liability (net)	4,033	3,452	5,069	4,954	4,830
Total debt	1,228	1,242	9,599	9,599	9,599
Total liabilities & equity	2,71,949	2,58,952	2,63,273	2,65,340	2,66,014
Net tangible fixed assets	17,576	26,353	31,191	42,831	48,492
Net intangible assets	253	307	307	307	307
Net ROU assets	0	0	0	0	C
Capital WIP	768	819	275	2,209	2,209
Goodwill	0	0	0	0	C
Investments [JV/Associates]	31,465	34,465	34,465	34,465	34,465
Cash & equivalents	2,13,117	1,98,126	2,16,315	2,06,870	2,05,388
Current assets (ex-cash)	56,040	51,207	59,954	65,772	70,156
Current Liab. & Prov.	47,270	52,325	79,233	87,115	95,003
NWC (ex-cash)	8,770	(1,118)	(19,279)	(21,343)	(24,847)
Total assets	2,71,949	2,58,952	2,63,273	2,65,340	2,66,014
Net debt	(2,11,890)	(1,96,884)	(2,06,716)	(1,97,271)	(1,95,789)
Capital employed	2,71,949	2,58,952	2,63,273	2,65,340	2,66,014
Invested capital	26,599	25,542	12,218	21,796	23,952
BVPS (Rs)	921.6	898.6	903.4	911.4	914.3
Net Debt/Equity (x)	(0.8)	(0.8)	(0.8)	(0.8)	(0.8)
Net Debt/EBITDA (x)	(4.0)	(3.0)	(2.3)	(1.9)	(1.7)
Interest coverage (x)	0.0	0.0	0.0	0.0	0.0
RoCE (%)	14.3	18.3	24.8	29.6	32.0

Source: Company, Emkay Research

Cash flows					
Y/E Mar (Rs mn)	FY22	FY23	FY24	FY25E	FY26E
PBT	61,901	74,086	98,220	1,15,115	1,24,156
Others (non-cash items)	0	0	0	0	0
Taxes paid	(17,015)	(19,184)	(23,826)	(27,743)	(29,922)
Change in NWC	6,009	7,234	10,171	2,063	3,505
Operating cash flow	29,983	43,305	60,758	33,969	81,352
Capital expenditure	(5,176)	(8,064)	(7,957)	(17,399)	(10,000)
Acquisition of business	(6,390)	(3,000)	0	0	0
Interest & dividend income	3,570	4,153	4,153	4,153	4,153
Investing cash flow	11,133	25,152	12,632	34,886	9,124
Equity raised/(repaid)	0	(30,939)	(39,307)	0	0
Debt raised/(repaid)	0	0	8,327	0	0
Payment of lease liabilities	0	0	0	0	0
Interest paid	(74)	(380)	(519)	(594)	(653)
Dividend paid (incl tax)	(40,490)	(40,470)	(39,614)	(38,525)	(85,306)
Others	57	306	231	0	0
Financing cash flow	(40,506)	(71,483)	(70,882)	(39,119)	(85,959)
Net chg in Cash	610	(3,026)	2,509	29,736	4,517
OCF	29,983	43,305	60,758	33,969	81,352
Adj. OCF (w/o NWC chg.)	23,974	36,071	50,587	31,906	77,847
FCFF	24,807	35,241	52,801	16,570	71,352
FCFE	28,290	38,999	56,419	20,130	74,852
OCF/EBITDA (%)	57.0	66.1	68.9	31.9	70.1
FCFE/PAT (%)	56.4	69.3	75.4	23.0	79.3
FCFF/NOPLAT (%)	64.4	74.0	81.8	21.2	84.1

Source: Company, Emkay Research

Source: Company, Emkay Research

Valuations and key R	atios				
Y/E Mar	FY22	FY23	FY24	FY25E	FY26E
P/E (x)	54.7	45.4	33.2	28.4	26.3
P/CE(x)	51.7	43.2	31.7	27.2	25.2
P/B (x)	9.8	10.0	10.0	9.9	9.9
EV/Sales (x)	7.2	6.5	5.1	4.2	3.9
EV/EBITDA (x)	45.6	36.0	25.8	21.5	19.7
EV/EBIT(x)	48.1	37.6	26.9	22.3	20.5
EV/IC (x)	90.2	92.2	186.3	104.8	95.5
FCFF yield (%)	1.0	1.5	2.3	0.7	3.1
FCFE yield (%)	1.1	1.5	2.3	0.8	3.0
Dividend yield (%)	1.6	1.6	1.6	3.4	3.8
DuPont-RoE split					
Net profit margin (%)	14.4	15.4	16.7	16.3	16.1
Total asset turnover (x)	1.2	1.4	1.7	2.0	2.2
Assets/Equity (x)	1.0	1.0	1.0	1.1	1.1
RoE (%)	18.4	21.6	29.7	35.0	37.6
DuPont-RoIC					
NOPLAT margin (%)	11.6	13.1	14.4	14.5	14.5
IC turnover (x)	0.0	0.0	0.0	0.0	0.0
RoIC (%)	145.8	182.6	341.7	458.5	371.1
Operating metrics					
Core NWC days	9.7	(1.1)	(15.7)	(14.5)	(15.4)
Total NWC days	9.7	(1.1)	(15.7)	(14.5)	(15.4)
Fixed asset turnover	7.5	7.3	7.6	7.6	7.1
Opex-to-revenue (%)	10.7	10.5	9.2	9.0	9.0

Source: Company, Emkay Research

This report is intended for team emkay@whitemarquesolutions com use and downloaded at 05/15/2024 10:24 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
25-Jan-24	7,598	6,800	Reduce	Chirag Jain
11-Jan-24	7,299	6,800	Reduce	Chirag Jain
30-Nov-23	6,091	5,190	Reduce	Chirag Jain
19-Oct-23	5,483	5,190	Hold	Chirag Jain
26-Jul-23	4,870	4,760	Hold	Chirag Jain
26-Apr-23	4,171	4,420	Hold	Chirag Jain
04-Apr-23	3,875	4,190	Hold	Chirag Jain

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014, EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information. it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 05/15/2024 10:24 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- EGESL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in 1. the securities recommended in this report as of April 19, 2024
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report 2. Disclosure of previous investment recommendation produced:
- З EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities 4. recommended in this report as of April 19, 2024
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the 5. subject company at the end of the month immediately preceding the April 19, 2024
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months. 6.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for
- investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	<15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkavglobal.com

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 05/15/2024 10:24 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject Company in the past 12 months. EGFSL or its associates may have received any compensation from the subject Company in the past 12 months. EGFSL or its associates may have received compensation from the subject Company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates for the subject company in the past twelve months.